Clinical trial
A Phase I Study of DT2219ARL, A Bispecific Singe Chain Immunotoxin for the Treatment of Relapsed or Refractory CD19(+), CD22(+) B-Lineage Leukemia or Lymphoma
NCT00889408 is registered in ClinicalTrials.gov with Masonic Cancer Center, University of Minnesota as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of DT2219ARL, A Bispecific Singe Chain Immunotoxin for the Treatment of Relapsed or Refractory CD19(+), CD22(+) B-Lineage Leukemia or Lymphoma
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 2, 2013
- Completion date
- July 21, 2014
- Enrollment
- 25 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.